Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes-Reference-Cited by-同舟云学术

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes

Published:2023-12-07 Issue:2 Volume:103 Page:437-442
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Barbui Tiziano^ORCID,Carobbio Alessandra,De Stefano Valerio,Alvarez-Larran Alberto,Ghirardi Arianna,Carioli Greta,Fenili Francesca,Rossi Elena,Ciceri Fabio,Bonifacio Massimiliano,Iurlo Alessandra,Palandri Francesca,Benevolo Giulia,Pane Fabrizio,Ricco Alessandra,Carli Giuseppe,Caramella Marianna,Rapezzi Davide,Musolino Caterina,Siragusa Sergio,Rumi Elisa,Patriarca Andrea,Cascavilla Nicola,Mora Barbara,Cacciola Emma,Calabresi Laura,Loscocco Giuseppe Gaetano,Guglielmelli Paola,Gesullo Francesca,Betti Silvia,Ramundo Francesco,Lunghi Francesca,Scaffidi Luigi,Bucelli Cristina,Cattaneo Daniele,Vianelli Nicola,Bellini Marta,Finazzi Maria Chiara,Tognoni Gianni,Rambaldi Alessandro,Vannucchi Alessandro Maria

Funder

Fondazione AIRC per la ricerca sul cancro ETS

AOP Health

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05577-9.pdf

Reference12 articles.

1. Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A et al (2022) Myeloproliferative neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(9):1033–1062

2. Tefferi A, Barbui T (2023) Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 98(9):1465–1487